At a glance
This program funds clinical translational research on tuberous sclerosis complex, including studies that move promising preclinical or clinical findings closer to diagnosis, prognosis, treatment, or clinical care. Eligible applicants include U.S. Department of War organizations and foreign or domestic, for-profit or nonprofit, public or private organizations; awards are made to organizations, not individuals. The announcement expects about $3.50 million to fund about two awards, with total costs capped at $1.60 million for single-PI applications and $1.90 million for partnering-PI applications, over a maximum period of 3 years. Cost sharing is not required. The program has no stated geographic restriction, but it does not support painful research involving domestic cats or dogs except for studies related to military or service animals.
What it funds
Official description from grants.gov
Summary: The fiscal year 2026 (FY26) Tuberous Sclerosis Complex Research Program (TSCRP) Clinical Translational Research Award (CTRA) supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis or treatment of tuberous sclerosis complex (TSC). Distinctive Features: This funding mechanism allows for multiple Principal Investigators (PIs). Only the initiating PI will submit a pre-application, but all PIs will need to submit full applications. The partnering PI(s) application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.
Who can apply
- Unrestricted